Study to Improve Brigatinib Treatment With Local Ablative Therapy in Adults With Advanced ALK-Positive Non-Small Cell Lung Cancer

What this Trial Is About

This trial investigates whether giving systemic Brigatinib along with local ablative therapy LAT at the time when Brigatinib is working best can improve outcomes for adults with advanced non-small cell lung cancer NSCLC that has an ALK gene rearrangement. This type of alteration leads to abnormal proteins causing cancer cells to multiply. The study involves participants whose cancer has responded or stabilized after 3 to 9 months of Brigatinib treatment and who have a limited number of metastatic lesions suitable for LAT. Participants who meet criteria will receive LAT such as surgery, stereotactic radiosurgery SRS, or percutaneous thermal ablation for liver or adrenal metastases, while continuing Brigatinib. The disease status will be evaluated between 3 to 9 months after starting Brigatinib to confirm tumor response or stabilization and check that all tumor targets are accessible to LAT as reviewed by an expert panel. During the study, participants will visit the clinic for eligibility assessment prior to LAT, receive LAT, then undergo regular check-ups every 8 weeks for the first year after LAT and every 12 weeks thereafter, for up to 3 years. Researchers will monitor progression-free survival and overall survival, along with safety and treatment duration. Assessments include imaging scans, laboratory blood tests, and pregnancy tests for women of childbearing potential.

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib